<DOC>
	<DOCNO>NCT01423396</DOCNO>
	<brief_summary>Three quarter patient Alzheimer 's disease least one vascular risk factor ( VRF ) . Vascular brain lesion present Alzheimer 's patient ( especially old one ) . This cerebrovascular disease potentiate Alzheimer 's lesion early-stage disease . Many research study show VRFs also risk factor Alzheimer 's disease ; true arterial hypertension dyslipidaemia particular , lesser extent , diabetes cardiopathy . Moreover , recent drug trial ( SYST-EUR , PROGRESS HOPE ) indicate antihypertensive medication prevent appearance dementia ( notably Alzheimer 's disease ) over-60 hypertensive subject . An observational study 233 Alzheimer 's patient average follow-up period 4 year show annual decline Mini-Mental State Examination ( MMSE ) score low patient VRFs treat patient VRFs treat ( 1.5 ± 2.5 point versus 2.5 ± 2 point , respectively ; p &lt; 0.04 ) .1 However , currently know whether optimal treatment VRFs influence progression prognosis Alzheimer 's disease . Answering question could significant impact public health .</brief_summary>
	<brief_title>Impact Controlling Vascular Risk Factors Progression Alzheimer 's Disease</brief_title>
	<detailed_description>It currently know whether optimum treatment VRFs influence progression prognosis Alzheimer 's disease . Our start hypothesis VRF control Alzheimer 's patient associate slow cognitive decline , less intense loss personnel independence few adverse event course disease ( cardiovascular cerebrovascular event , behavioural disorder , caregiver burden , hospitalization death ) . COVARAD study randomize , control , multicentre study compare 2 VRF care strategy mild-to-moderate ( MMSE &gt; 18 ) Alzheimer 's disease patient least one VRF . The objective work evaluate effect `` optimal '' care strategy , strict compliance French HAS guideline concern target blood pressure , glycaemia blood lipid level , cognitive function mild-to-moderate Alzheimer 's patient ( MMSE score &gt; 18 ) , comparison control group ( i.e . receive standard care primary care physician ) . The study test hypothesis whereby `` optimal '' care 3 main modifiable VRFs associate slow cognitive decline Alzheimer 's disease patient ( evaluate ADAS-cog score ) , compare standard care compare MMSE , MoCA VADAS-cog score , mood behaviour ( MADRS NPI ) , loss independence ( ADCS-ADL ) , occurrence cardiovascular cerebrovascular event , number length hospitalisation , caregiver burden ( Zarit scale ) , institutionalization survival two group ( i.e . depend whether VRFs manage optimally ) . This study could influence clinical practice . If VRF control influence progression Alzheimer 's disease , information campaign could modify practice significant impact public health . An independent Data Safety Monitoring Board set monitor diabetic patient , view risk relate `` optimal '' care ( ACCOR ADVANCE study ) . Nevertheless , risk adverse event limit raise threshold value glycated haemoglobin 8 % .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion Subjects age 60 Subjects Alzheimer 's disease , accord NINCDS/ADRDA diagnostic criterion 71 MMSE &gt; 18 Subjects least one VRF ( whether treat ) : arterial hypertension ( define SBP/DBP ≥ 140/90 mmHg least three different consultation , ambulatory measurement , &gt; 130/80 mmHg Holter recorder &gt; 135/85 mmHg selfmeasurement device ) , type 2 diabetes ( define glycaemia value 1.26 g/l ( 7 mmol/l ) 8hour fast ( confirm two occasion ) , dyslipidaemia ( define LDL cholesterol level &gt; 1.6 g/l 1.3 1 g/l , depend patient 's risk level ) Subjects agree participate study ( provision inform consent ) . Subjects accompany person likely provide information patient ( visit phone ) . Exclusion criteria Any disease might interfere evaluation cognitive disorder . No formal education poor understanding French ( interfere administration neuropsychological test ) . Major physical problem likely interfere administration test ( poor eyesight , hearing , etc. ) . NonAlzheimer 's dementia ( isolated vascular dementia , Lewy body dementia , frontotemporal dementia , etc . ) Psychotropic drug likely modify patient 's nonstabilized cognitive state . Patients history cardiovascular event include ( randomization balance term criterion ) . Participation therapeutic clinical trial study period .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>cardiovascular risk factor</keyword>
</DOC>